VDRM ViaDerma Inc

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

A second shipment of 500,000 units is expected to be made by the end of October

LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024.

This milestone marks a significant step forward in ViaDerma’s international expansion strategy, as the company continues to meet the growing global demand for its products. The timely execution of this shipment demonstrates ViaDerma’s commitment to delivering high-quality pharmaceutical solutions to key markets around the world.

A second shipment of an additional 500,000 units is already in preparation and is expected to be dispatched before the end of October 2024. This next phase of shipments highlights ViaDerma’s dedication to ensuring a consistent supply to its partners in Nigeria, aligning with the company’s broader vision of expanding into emerging markets.

Additionally, ViaDerma is pleased to announce that CEO Dr. Christopher Otiko has successfully returned from his recent follow-up trip to Dubai, where he engaged with key partners in the region. The trip was highly productive, with strong continued interest from local partners, further solidifying the Company’s plans to strengthen alliances and expand distribution across the Middle East.

“We are thrilled to have successfully completed our first large-scale shipment to Nigeria, furthering our mission to make wound care more accessible globally,” said Dr. Christopher Otiko, CEO of ViaDerma. “We look forward to building on this momentum with our upcoming shipment in October as we continue to expand our presence across Africa, the Middle East and other regions.”

ViaDerma’s innovative products, including its patented transdermal delivery systems, have been well-received in international markets, helping address the growing need for effective wound care solutions. The company remains committed to increasing access to life-saving medications and wound care products in underserved regions.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: 

Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:

Investor Relations

Email:

Phone: 310-734-6111



EN
10/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ViaDerma Inc

 PRESS RELEASE

ViaDerma Announces Significant 2024 Achievements and International Exp...

ViaDerma Announces Significant 2024 Achievements and International Expansion LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a landmark year marked by significant global expansion and operational milestones. As the company continues its mission to deliver cutting-edge pharmaceutical products to underserved markets, 2024 has proven to be a transformative year. ViaDerma’s expansion efforts in 2024 have led to a remarkable increase in personnel, with...

 PRESS RELEASE

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving...

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves. Financial Highlights for Q2 2024: Revenue: ViaDerma maintained stead...

 PRESS RELEASE

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

ViaDerma Completes First Shipment of 500,000 Units to Nigeria A second shipment of 500,000 units is expected to be made by the end of October LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024. This milestone marks a significant st...

 PRESS RELEASE

ViaDerma Announces Shipment of 500,000 Units of its Flagship Product t...

ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is excited to announce that a shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic, has been in production and is being prepared for delivery to Nigeria before the end of August 2024. This marks a significant milestone in ViaDerma’s ongoing efforts to expand its global footprint and provide effective wound care solutions across Africa. In addition to t...

 PRESS RELEASE

ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six ...

ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), a leader in innovative wound care solutions, proudly announces the successful completion of pivotal distribution agreements across the Middle East and Eastern Europe. Dr. Christopher Otiko, President of ViaDerma, recently returned from the United Arab Emirates, where he met with representatives from two leading distribution companies in Dubai and finalized agreements centered around ViaDerma's flagship topical antibiotic produc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch